uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
October 16, 2018 07:00 ET
|
uniQure Inc.
~ New Data Further Demonstrating Leading Gene Therapy Manufacturing and Administration Capabilities ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 16, 2018 (GLOBE NEWSWIRE) -- uniQure N.V....
uniQure to Participate in Multiple Upcoming Industry Conferences
September 28, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
September 24, 2018 07:00 ET
|
uniQure Inc.
~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...
uniQure to Participate at Multiple Upcoming Conferences
August 30, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces New Appointments to its Board of Directors
June 13, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 13, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
May 21, 2018 07:00 ET
|
uniQure Inc.
-- New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 -- -- Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients -- -- Data Presented at the...
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
May 18, 2018 07:00 ET
|
uniQure Inc.
-- Preclinical Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Chicago -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 18, 2018 (GLOBE NEWSWIRE)...
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
May 07, 2018 11:47 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 07, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Proposed Public Offering
May 01, 2018 16:04 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
April 30, 2018 07:05 ET
|
uniQure Inc.
~ Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence in third quarter of 2018 ~ IND filing for AMT-130 in...